At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
S-Equol in Alzheimer's Disease 2 (SEAD2) Trial
In Brief
A Phase 2 clinical trial evaluating S-equol and Placebo and Placebo and S-equol for Alzheimer Disease. Completed, enrolled 40 participants across 2 sites.
Detailed Summary
By doing this study researchers hope to learn if S-equol, a compound that acts like estrogen in the body, causes an increase in mitochondrial activity. Researchers also hope to determine the safety and tolerability of a therapeutic dose of S-equol and whether or not it influences cognition.
Study Details
Timeline
Interventions
S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.